|
Authors (country) | Num. of case (s) | Age/sex of patient (s) | Vaccine regimen | Onset milestones | Concomitant drugs | Histopathology (DIF) | Treatment (s) (response) |
|
Our cases (Vietnam) | 2 | 53/female | Mixed 1 AZD1222 dose following 3 BBIBP-CorV doses | 3 weeks following 4th AZD1222 dose in the mixed regimen | Amlodipine | Acantholysis above the stratum basalis, dermal lymphocyte, and neutrophil infiltration (intraepidermal IgG and C3) | Corticosteroid, rituximab (almost complete response in 3 weeks) |
30/female | 2 doses of mRNA-1273 | 2 months following 2nd mRNA-1273 dose | None | Acantholysis above the stratum basalis (intraepidermal IgG and C3) | Topical and systemic corticosteroid (almost complete response in 4 weeks) |
|
Pourani et al. [5] (Iran) | 1 | 75/male | 3 doses of BBIBP-CorV | 2 weeks after 3rd dose | None | Superficial epidermal bullae, mild spongiosis, superficial dermal perivascular inflammation (intraepidermal IgG and C3) | Topical corticosteroid, rituximab (significant response in 4 weeks) |
|
Lua et al. [6] (Singapore) | 1 | 83/male | 2 doses of BNT162b2 | 2 days after 2nd dose | N/A | Subacute spongiotic dermatitis (C3 dermal-epidermal junction and intercellular deposition) | Prednisolone (good clinical response) |
|
Corrá et al. [7] (Italy) | 2 | 80/male | 3 doses of BNT162b2 | 17 days after 3rd dose | Amiloride, hydrochlorothiazide, esomeprazole | Subcorneal acantholysis with neutrophilic infiltration within the blister (PT1: negative; PT2: intercellular IgG deposits) | Oral corticosteroid, rituximab, MMF (probably good clinical response) |
66/female | 2 doses of BNT162b2 | 4 weeks after 2nd dose | Rabeprazole, ticlopidine, atorvastatin, amlodipine, hydrochlorothiazide |
|
Hali et al. [8] (Morocco) | 1 | 50/female | 2 doses of BNT162b2 | 15 days after 2nd dose | None | Superficial epidermal blistering process, intact basal layer, intraepidermal eosinophils (intracellular IgG and C3) | Oral corticosteroid (complete response in 3 weeks) |
|
Yıldırıcı et al. [9] (Turkey) | 1 | 65/male | 2 doses of BNT162b2 (6 weeks apart) | 1 months after 1st dose; 2 weeks after 2nd dose | Nebivolol, valsartan‐hydrochlorothiazide | Intraepidermal acantholytic blister, abundant neutrophils, and scarce eosinophils (intercellular IgG and C3) | Oral corticosteroid, azathioprine (marked response in 2 weeks) |
|